Health Care M&A Activity Is Set to Surge Post-Pandemic

The COVID-19 pandemic has fueled and accelerated merger and acquisition activity in the health care sector, according to the 2021 HealthLeaders Mergers, Acquisitions, and Partnerships Survey conducted by the HealthLeaders Intelligence Unit. The analysis of 119 completed surveys of executives at health systems, hospitals, physician organizations, skilled nursing and assisted living facilities and other provider entities shows that while the pandemic delayed or stalled 49% of respondents’ M&A plans, 90% expect their organizations’ M&A activity to increase or remain the same within the next three years. The top driver of M&A activity is increasing scale to improve negotiations with payers (66%), followed by improving patient care (38%). Meanwhile, data compiled by market research firm Mercom Capital Group shows that digital health M&A set a record in the first half of 2021, with 136 digital health transactions compared to 83 during the same period last year.

NOTE: Survey results do not always add up to 100% due to rounding.

SOURCES: “No Drop-Off for Healthcare M&A Post-Pandemic,” HealthLeaders, July/August 2021. “2021 HealthLeaders Mergers, Acquisitions, and Partnerships Survey,” HealthLeaders Intelligence Unit. “Digital Health Funding and M&A, 2021 First Half Report,” Mercom Capital Group. Visit https://bit.ly/3gudoub.

This infographic was reprinted from AIS Health’s weekly publication Health Plan Weekly.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 18

FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs’ Uptake

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-drug-benefits-OptumRx-Spotlights-Two-Drugs-That-Treat-Rare-Liver-Diseases.jpg
November 18

Oncologists Show Interest in Prescribing New CML STAMP Inhibitor Scemblix

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-RADAR-on-Drug-Benefits-Eli-Lilly-Pounces-on-Flailing-Aduhelm-With-Competing-Drug.jpg
November 18

Eli Lilly Pounces on Flailing Aduhelm With Competing Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today